RGNX: Regenxbio Inc Company Profile & Statistics

About

REGENXBIO Inc. is a biotechnology company. The Company focuses on the development, commercialization and licensing of recombinant adeno-associated virus gene therapy. Its products candidates include RGX-501, for the treatment of homozygous familial hypercholesterolemia which uses the AAV8 vector to deliver the human low-density lipoprotein receptor gene to liver cells; RGX-111, for the treatment of Mucopolysaccharidosis Type I which uses the AAV9 vector to deliver the human a-l-iduronidase gene to the central nervous system; RGX-121, for the treatment of Mucopolysaccharidosis Type II; RGX-314, for the treatment of wet age-related macular degeneration and RGX-321, for the treatment of X-linked retinitis pigmentosa. REGENXBIO Inc. is headquartered in Rockville, Maryland.

Info & Links

CEO

Kenneth T. Mills

Headquarters

9804 MEDICAL CENTER DRIVE
ROCKVILLE, MD 20850, UNITED STATES

Auditor

PricewaterhouseCoopers LLP

Share holders

Employees

344

Regenxbio Inc Statistics

Valuation Measures

Market Capitalization²

416.63M

Enterprise Value

360.01M

Enterprise Value/EBITDA(ttm)

-1.55

Price to Earnings Ratio(ttm)

Price to Sales(ttm)

4.86

Price to Book(mrq)

1.36

Price to Cash(ytd)

Profitability

Gross Margin(ttm)

55.84%

Operating Margin(ttm)

-283.19%

Profit Margin(ttm)

-293.12%

Return on Equity(ttm)

-70.65%

Return on Invested Capital(ttm)

-71.37%

Return on Assets(ttm)

-41.68%

Income Statement

Revenue(ttm)

84.33M

Revenue Per Share(ttm)

1.70

Gross Profit(ttm)

45.84M

EBITDA(ttm)³

-232.62M

Net Income Available to Common(ttm)

-238.81M

Diluted EPS(ttm)

-5.03

Share Statistics

Beta (5Y Monthly)

1.24

52-Week Change

-57.97%

S&P 500 52-Week Change

27.88%

S&P 500 Member

Yes

Stock Optionable

Yes

Total Shares Outstanding¹

49.55M

Dividend Yield

0.00%

Float⁴

43.04M

% Held by Insiders

13.13%

% Held by Institutions

88.08%

Balance Sheet

Total Cash(mrq)

255.46M

Total Cash Per Share(mrq)

5.16

Total Debt(mrq)

0.00

Total Debt/Equity(mrq)

0.00%

Current Ratio(mrq)

3.05%

Quick Ratio(mrq)

3.05%

Book Value Per Share(mrq)

6.08

Cash Flow

Operating Cash Flow Per Share(ytd)

-2.79

Free Cash Flow(ytd)

-142.86M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. All numbers are rounded to the closest decimal.

1 Total Shares outstanding is taken from the most recently filed quarterly or annual report.
2 Market Cap is calculated using total shares outstanding and the most recent share price.
3 EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
4 The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.

RGNX

Regenxbio Inc

Regenxbio Inc Profile